Rare disease care is missing from climate adaptation planning
Climate–health adaptation often centers on exposures that are common, visible, and easy to count: heat stress, floods, air pollution, vector-borne infection, and emergency surge capacity. Rare disease sits outside that frame, yet the consequences of disruption are often more severe because patients may depend on time-sensitive medication, cold-chain storage, specialist follow-up, device support, or travel to a limited number of centers. In a short comment published in Nature Climate Change, Teguh Haryo Sasongko argues that rare diseases are an overlooked dimension of climate–health adaptation and that resilient systems must protect uncommon vulnerabilities as carefully as common ones.
The central premise is straightforward and difficult to ignore. Fairness in climate planning cannot stop at population averages when some patients have almost no margin for missed care.
Why climate shocks are a different threat for rare disease
Rare disease populations are often small, geographically dispersed, and clinically complex. Those features make them especially vulnerable when climate events interrupt transport, electricity, communications, and health service continuity. A patient who can miss a routine appointment and reschedule later is not comparable to a patient whose next infusion, enzyme replacement, ventilatory support, or dietary supply is tied to a fixed timetable and a narrow therapeutic window. When infrastructure fails, the harm is not abstract. It becomes a missed dose, a delayed diagnosis, a postponed procedure, or a family forced to choose between personal safety and preserving access to care.
Climate adaptation plans rarely treat that chain of failure as a distinct clinical problem. They tend to assume that resilience can be built by protecting general access to acute and primary care. Rare disease breaks that assumption because a single point of failure may be enough to destabilize disease control. The biology of these disorders compounds the logistical risk: many are progressive, multisystemic, and unforgiving of interruption. The clinical cost of discontinuity can therefore exceed the visible footprint of the weather event itself.
Access, equity, and the ethics of preparedness
Sasongko frames this gap as an issue of both safety and fairness. That framing is difficult to dispute. Climate resilience is not complete if it protects only the most common patient pathways while leaving highly specialized care exposed to preventable interruption. Patients with rare disease already face diagnostic delay, fragmented expertise, and uneven access to specialty services. Climate-related disruption adds a second layer of vulnerability, especially in settings where care is centralized and patients must travel long distances to reach experienced clinicians.
This is where adaptation policy can fail quietly. Emergency plans may account for bed capacity, evacuation, or medication stockpiles in broad terms, yet still miss the specific needs of rare disease communities. A health system can appear prepared on paper while leaving families without a route to refrigeration, refills, continuity of specialist review, or backup plans when transportation breaks down. Preparedness should be judged not only by the number of people covered, but by whether the most fragile care pathways remain intact when the environment turns unstable.
A systems problem, not an orphaned niche
Rare disease is often treated as a specialty silo. Climate adaptation requires the opposite approach. Health systems need to map which rare disease services are location-sensitive, which therapies depend on uninterrupted supply chains, which patients rely on device power or home-based technology, and which regions face the greatest overlap between climate exposure and specialist scarcity. Those questions are operational, not theoretical. They determine whether continuity of care survives a heatwave, flood, wildfire, or transport collapse.
The policy implications extend beyond hospital walls. Community resilience plans, disaster response protocols, and public health warning systems should be built with rare disease access in mind. So should digital tools, referral networks, and cross-border planning where patients depend on a small number of centers or experts. The climate burden may be general, but the clinical vulnerabilities are not. Some are sharply concentrated in groups that health planning has historically overlooked.
Evidence gaps remain wide, but inaction is already a decision
The comment does not present a trial, cohort study, or quantitative estimate. Its force lies elsewhere: it points to a neglected category of risk that becomes more consequential as climate hazards intensify. References cited with the piece include work on rare disease prevalence, regional studies, and broader frameworks for climate-resilient health systems, but the article’s own message is conceptual and policy-facing rather than empirical. That matters because the absence of robust rare-disease-specific climate data should not be mistaken for the absence of risk.
Health systems do not need perfect datasets to recognize a preventable failure mode. They need enough clinical awareness to identify where weather-related disruption would sever access, and enough planning discipline to protect those pathways before the next emergency arrives. Rare disease patients cannot absorb repeated interruptions the way larger patient groups sometimes can. In a climate-stressed health system, continuity is not a luxury for these patients; it is the condition that keeps treatment from unraveling.